The Sleep and Breathing Health segment's revenue increased by 11% year-over-year, indicating continued strong performance in the core business. This growth was primarily driven by increased demand and unit sales of devices and masks.

The Residential Care Software segment grew by 13% year-over-year, demonstrating successful expansion in the HME and MEDIFOX DAN verticals. This indicates a successful diversification strategy.

ResMed announced a new operating model with dedicated leadership in Product, Revenue, and Marketing, aiming to increase product development velocity and sharpen customer focus. This strategic shift is expected to drive greater value and improved care throughout the care continuum.

The increase in gross margin to 58.6% is attributed to manufacturing efficiencies and component cost improvements, reflecting effective cost management. These improvements directly contribute to higher profitability.

ResMed invested $79.5 million in research and development, representing 6.5% of net revenues, to develop innovative products and solutions. This commitment to R&D supports long-term growth and competitiveness.

Cash provided by operating activities increased to $325.5 million, reflecting efficient management of working capital and strong operational performance. This robust cash flow provides financial flexibility for strategic investments and shareholder returns.

ResMed is involved in patent infringement litigation with New York University, potentially impacting the AutoSet or AutoRamp features of ResMed's AirSense 10 AutoSet flow generators. While the PTAB ruled in ResMed's favor, NYU has appealed, and the outcome remains uncertain.

Cleveland Medical Devices Inc. filed suit for patent infringement against ResMed Inc. asserting that numerous ResMed connected devices, when combined with certain ResMed data platforms and/or software, including AirView and ResScan, infringe one or more of seven Cleveland Medical patents. ResMed has filed a petition with the PTAB seeking review of the validity of U.S. Patent No. 10,076,269.

ResMed is exposed to foreign currency exchange rate fluctuations, which can impact financial results. Movements in international currencies against the U.S. dollar positively impacted net revenue by approximately $3.9 million for the three months ended September 30, 2024.

The 11% revenue increase in the Sleep and Breathing Health segment demonstrates ResMed's ability to maintain and grow its market share in the core business. This growth is driven by increased demand and unit sales of devices and masks.

The 13% growth in the Residential Care Software segment showcases ResMed's successful diversification strategy and ability to compete in new markets. This expansion reduces reliance on the core Sleep and Breathing Health business.

ResMed's commitment to research and development, with $79.5 million invested in the quarter, supports the development of new and innovative products. This continuous innovation is essential for maintaining a competitive edge in the medical device industry.

The increase in gross margin is attributed to manufacturing efficiencies and component cost improvements, demonstrating successful operational improvements. These efficiencies contribute to higher profitability.

Selling, general, and administrative expenses increased by 7%, which is less than the revenue growth rate of 11%. This indicates effective cost management and operational efficiency.

Strong cash flow from operations reflects efficient management of working capital. This indicates ResMed's ability to convert sales into cash effectively.

ResMed invested $79.5 million in research and development, representing 6.5% of net revenues, demonstrating a strong commitment to innovation. This investment is crucial for developing new products and solutions.

The AirSense 11 device features a touch screen, algorithms for new patients, digital enhancements, and over-the-air update capabilities. These features highlight ResMed's focus on incorporating advanced technology into its products.

ResMed's residential software platforms, combined with cloud-based remote monitoring and therapy management systems, provide connected care solutions. These platforms improve patient outcomes and efficiencies for customers.

ResMed repurchased $50.0 million of treasury stock, reflecting a commitment to returning value to shareholders. This repurchase program demonstrates confidence in the company's financial performance and future prospects.

ResMed paid cash dividends of $0.53 per common share, totaling $77.9 million, demonstrating a consistent return of capital to shareholders. The board also declared a similar dividend for the next quarter.

Acquisitions of Brightree, HEALTHCAREfirst, MatrixCare, and MEDIFOX DAN have expanded ResMed's capabilities and market reach. These acquisitions contribute to the growth of the Residential Care Software segment.

The provided document does not contain specific details regarding ResMed's ESG initiatives. Further information would be needed to assess their environmental, social, and governance practices.

ResMed's products and solutions are designed to support the shift in care from hospitals to the home and lower-cost settings, aligning with global healthcare trends. This trend creates a favorable market environment for ResMed.

An increasing awareness of SDB and respiratory conditions like COPD is driving growth. This heightened awareness leads to increased diagnosis and treatment, benefiting ResMed's business.

Changes or developments in healthcare reform, social, macroeconomic, market, legal or regulatory circumstances, including the impact of public health crises, are important factors to consider in evaluating such forward-looking statements